Related references
Note: Only part of the references are listed.p53 and MDM2 in Renal Cell Carcinoma Biomarkers for Disease Progression and Future Therapeutic Targets?
Aidan P. Noon et al.
CANCER (2010)
MDM2 promotes cell motility and invasiveness through a RING-finger independent mechanism
Radoslaw Polanski et al.
FEBS LETTERS (2010)
Molecular Signatures of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after Nephrectomy
Tobias Klatte et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Suppression of Hypoxia-inducible Factor 2α Restores p53 Activity via Hdm2 and Reverses Chemoresistance of Renal Carcinoma Cells
Andrew M. Roberts et al.
CANCER RESEARCH (2009)
Diagnostic and Prognostic Molecular Markers for Renal Cell Carcinoma: A Critical Appraisal of the Current State of Research and Clinical Applicability
Christian Eichelberg et al.
EUROPEAN UROLOGY (2009)
p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug
Shu-Ping Wang et al.
NATURE CELL BIOLOGY (2009)
Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
Sanjeev Shangary et al.
Annual Review of Pharmacology and Toxicology (2008)
Regulation of angiogenic factors by HDM2 in renal cell carcinoma
Veronica A. Carroll et al.
CANCER RESEARCH (2008)
The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer
William G. Kaelin
NATURE REVIEWS CANCER (2008)
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype:: Lessons from recent developments in the IARC TP53 database
Audrey Petitjean et al.
HUMAN MUTATION (2007)
Targeted molecular therapy for renal cell carcinoma
Brian R. Lane et al.
UROLOGY (2007)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Regulating the p53 pathway:: in vitro hypotheses, in vivo veritas
Franck Toledo et al.
NATURE REVIEWS CANCER (2006)
MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation
Jer-Yen Yang et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction
Ke Ding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
2004 WHO classification of the renal tumors of the adults
A Lopez-Beltran et al.
EUROPEAN UROLOGY (2006)
Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry
R Nenutil et al.
JOURNAL OF PATHOLOGY (2005)
p53 regulation and function in renal cell carcinoma
HE Warburton et al.
CANCER RESEARCH (2005)
p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma
O Shvarts et al.
JOURNAL OF UROLOGY (2005)
Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: A systematic analysis of primary and metastatic tumor tissue
R Zigeuner et al.
UROLOGY (2004)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Using protein expressions to predict survival in clear cell renal carcinoma
HL Kim et al.
CLINICAL CANCER RESEARCH (2004)
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans
GL Bond et al.
CELL (2004)